1. Medicines
  2. Cardio-Metabolic
  3. LEQVIO®▼ (inclisiran)
  4. LEQVIO® mechanism of action

Prescribing information

 

LEQVIO®▼ (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2,3

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

 

For full safety information, please refer to the GB and NI Summary of Product Characteristics.

 

LEQVIO®▼ (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1,2

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

 

For full safety information, please refer to the GB and NI Summary of Product Characteristics.

 

LEQVIO® mechanism of action

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

leqvio-moa-cycling-icon

LEQVIO® acts in the body in a targeted way to increase LDL-C receptor cycling and expression and help lower LDL-C levels in circulation.1,2

LEQVIO® works differently from other LDL-C-lowering therapies by preventing the production of PCSK9 in the liver.1–3,5

leqvio-moa-infographic

What makes it innovative?

Instead of blocking circulating PCSK9 like other LDL-C-lowering therapies, LEQVIO®, as an siRNA therapy, interferes with the RNA that codes for this protein, reducing its production in the first place.1–3,5

Watch the video below to learn more about the mechanism of action of LEQVIO®.

 

 

The potential benefits of LEQVIO® and its properties:

LEQVIO® prevents the production of PCSK9 protein in the liver, with an extended duration of effect6
 
LEQVIO® works selectively in the liver by harnessing the body’s process of RNAi, which is restricted to the cytoplasm meaning it has no impact on DNA6,7
Chemical modifications increase the stability of LEQVIO® by decreasing its susceptibility to degradation from exonucleases and endonucleases6
LEQVIO® is slowly released from the hepatic endosomes into the cytoplasm6
 
 

 

Icon of a target

The distinct mechanisms of action of LEQVIO® and statins provide complementary LDL-C reduction to help more patients reach their LDL-C goals1,2,8

Learn more about the efficacy of LEQVIO®

DNA, deoxyribonucleic acid; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; RNA, ribonucleic acid; RNAi, ribonucleic acid interference; siRNA, small interfering RNA.

References:

  1. LEQVIO® Great Britain. Summary of Product Characteristics.
  2. LEQVIO® Northern Ireland. Summary of Product Characteristics.
  3. Stoekenbroek RM, et al. Future Cardiol 2018;14(6):433–442.
  4. Lamb YA. Drugs 2021;81(3):389–395.
  5. Klinovski M, et al. Inclisiran: a small interfering RNA molecule for treating hypercholesterolemia. Ottawa: CADTH; 2019. CADTH Issues in Emerging Health Technologies; Issue 180.
  6. Khvorova AN, Engl J Med 2017;376(1):4–7. 
  7. Fitzgerald K, et al. N Engl J Med 2017;376(1):41–51.
  8. Nordestgaard BG, et al. Nat Rev Cardiol 2018;15(5):261–272.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.

Rate this content: 
Average: 5 (5 votes)
UK | October 2023 | 301970
Cardio-metabolic
Article

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com